This site uses cookies to ensure the best viewing experience for our readers. Read more about it Got it

Brief

Singapore’s VisVires Backs Israeli Shrimp-Health Startup ViAqua

ViAqua’s first product prevents and treats several ailments in shrimp, including white spot syndrome virus

Tofi Stoler 13:3313.12.18
Singapore-based VisVires New Protein Master Fund Pte. Ltd. (VVNP), the food and feed investments division of VisVires Capital Asia Pte. Ltd. has invested in Israel-based medical aquafarming startup ViAqua Therapeutics Ltd., VVNP announced Wednesday. The financial terms of the investment were not disclosed.

 

Founded in 2014 and based in the Galilee, ViAqua develops a particle-based method for orally administering antiviral medication to shrimp. ViAqua’s first product, expected to go on the market in the next few months, prevents and treats several ailments including white spot syndrome virus, a highly contagious and deadly virus. Previous investors in ViAqua include Dutch animal feed company Nutreco NV, Singapore-listed, Israel-based venture firm Trendlines Group Ltd., and Israeli research university Technion Israel Institute of Technology.

 

Shrimp (illustration). Photo: Shutterstock Shrimp (illustration). Photo: Shutterstock

 

Cancel Send
    To all comments